Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2004-03-04
2008-10-21
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S141100, C424S142100, C424S154100, C530S387100, C530S388100, C530S388150, C530S388220
Reexamination Certificate
active
07438905
ABSTRACT:
Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositions for suppressing, treating, or preventing graft rejection comprising a substance having an activity to modulate signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5747461 (1998-05-01), Markov
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bedner et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6531505 (2003-03-01), Xu et al.
patent: 7132099 (2006-11-01), Kroczek
patent: 2002/0115831 (2002-08-01), Tamatani et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2002/0177191 (2002-11-01), Kroczek
patent: 2002/0182667 (2002-12-01), Kroczek
patent: 2004/0229790 (2004-11-01), Tezuka et al.
patent: 752433 (1999-04-01), None
patent: 19821060 (1999-04-01), None
patent: 0 984 023 (2000-03-01), None
patent: 1 125 585 (2001-08-01), None
patent: 5-72204 (1993-03-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/11909 (1998-03-01), None
patent: WO 98/19706 (1998-05-01), None
patent: WO 98/37415 (1998-08-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 99/15553 (1999-04-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: WO 02/44364 (2001-06-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/70010 (2002-09-01), None
patent: WO 02/76504 (2002-10-01), None
Huang, Pharmacology and Therapeutics, 2000, 86:201-215.
English translation of WO 02/070010.
The Merck Manual of Diagnosis and Therapy (Merck Research Laboratories, 1999, 17th Edition, pp. 1072-1073).
Waldmann et al., Phil. Trans. R. Soc. Lond. B 2001, vol. 356, pp. 659-663.
Samstein et al., Phil. Trans. R. Soc. Lond. B 2001, vol. 356, pp. 749-758.
Calne R., Phil. Trans. R. Soc. Lond. B 2001, vol. 356, pp. 767-771.
Dai et al., (1999) “The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection,” Current Opinion in Immunology, vol. 11, No. 5, pp. 504-508.
Nanji et al., (2003) “Combination Therapy With Anti-ICOS and Cyclosporine Enhances Cardiac but Not Islet Allograft Survival,” Transplantation Proceedings, vol. 35, No. 7, pp. 2477-2478.
Abbas, “T-cell stimulation: an abundance of B7s,” Nat Med. 5(12):1345-6 (1999).
Abrams et al., “CTLA41g-mediated blockage of T-cell constimulation in patients with psoriasis vulgaris,” J. Of Clin. Invest. 103(9):1243-1252 (1999).
Aicher et al., “Characterization of human inducible costimulator ligand expression and function,” J. Of Immunology 164:4689-4696 (2000).
Akbari et al., “Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperractivity,” Nature Medicine 8(9):1024-1032 (2002).
Andersen et al., “Allelic variation of the inducible costimulator (ICOS) gene: detection of polymorphisms, analysis of the promoter region, and extended haplotype estimation,” Tissue Antigens 61: 276-285 (2003).
Ara et al., “Potent activity of soluble B7RP-1-FC in therapy of murine tumors in syngeneic hosts,” Int. J. Cancer 103:501-507 (2003).
Arimura et al., “A co-stimulatory molecule on activated T cells, H4/ICOS, delivers specific signals in Thcells and regulates their responses,” International Immunology 14(6):555-566 (2002).
Bojarth, “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulatory receptors,” J. Mol. Model 5:169-176 (1999).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol. 30:3707-3717 (2000).
Bennett et al., “Program death-1 engagement upon TCR activation has distinct effects on costiumulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses” J. of Immunol. 170:711-718 (2003).
Bensimon et al., “Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements,” Embo J. 13(13):2951-62 (1994).
Bertram et al., “Role of ICOS versus CD28 in antiviral immunity,” Eur. J. Immunol. 32:3376-3385 (2002).
Biacone et al., “Lymphocyte costimulatory receptors in renal disease and transplantation,” J. Nephrol 15:7-16 (2002).
Blazar et al., “CD4+cells tolerized ex vivo to host alloantigen by anti-CD40 ligand . . . antigen response,” J. Clin. Invest. 102(3):473-482 (1998).
Blazar et al., “Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly . . . donor grafts,” Blood 85(9):2607-2618 (1995).
Bonhagen et al., “ICOS+Th Cells produce distinct cytokines in different mucosal immune responses,” Eur. J. Immunol. 33:392-401 (2003).
Brodie et al., “LICOS, a primordial costimulatory ligand?” Current Biology 10(6):333-336 (2000).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol. 29:2863-2874 (1999).
Buonfiglio et al., “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical,” Eur. J. Immunol. 30:3463-3467 (2000).
Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).
Campbell et al., “Separable effector T cell populations specialized for B cell help or tissue inflammation,” Nat Immunol. 2(9):876-81 (2001).
Carreno et al., “The B7 family of ligands and its receptors,” Annu. Rev. Immunol. 20:29-53 (2000).
Chambers, “The expanding world of co-stimulation: the two-signal model revisted,” Trends in Immunology 22(4):217-223 (2001).
Chapoval et al., “B7-H3: a constimulatory molecule for T cell activation and IFN-gamma production,” Nat Immunol. 2(3):269-74 (2001).
Cocks et al., “A novel receptor involved in T-cell activation,” Nature, 376:260-263 (1995).
Coyle et al., “The CD28-related molecule ICOS is required for effective T cell-dependent immune responses,” Immunity 13:95-105 (2000).
Deng et al., “Critical role of CD81 in cognate T-B cell interactions leading to Th2 responses,” International Immunology 14(5):513-523 (2002).
Dong et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nat. Med. 5(12):1365-9 (1999).
Dong et al., “Cutting Edge: Critical role of inducible costimulator in germinal center reactions” The J. Immunol. 166:3659-3662 (2001).
Dong et al., “ICOS co-stimulatory receptor is essential for T-cell activation and function,” Nature 409:97-101 (2001).
Eljaschewitsch et al., “Identification of a novel activation antigen on human CD4+ T cells,” Immunobiol., 194(1-3):27 (1995).
Feito et al., “Mechanisms of H4/ICOS costimulation: effects on proximal TCR signals and MAP kinase pathways,” Eur. J. Immunol. 33:204-214 (2003).
Flesch, “Inducible costimulator (ICOS),” J. of Biol. Regul.Homeost. Agents 16:214-216 (2002).
Flesch, “Inducible costimulator-ligan
Isobe Mitsuaki
Suzuki, legal representative Atsuko
Fish & Richardson P.C.
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
Methods of suppressing, treating, or preventing graft... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of suppressing, treating, or preventing graft..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of suppressing, treating, or preventing graft... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4007303